Posted from: Monday, March 02, 2015 - 05:10 PM - Present

Ibrance Now Available for Breast Cancer

The U.S. Food and Drug Administration (FDA) granted Pfizer accelerated approval for Ibrance (palbociclib), to be used in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

The recommended starting dose is a 125mg capsule once daily taken with food for 21 days followed by 7 days off treatment for each 28 day cycle.

Pfizer launched Ibrance upon approval and it is available through a limited network of specialty pharmacies. Ibrance is expected to cost approximately $118,200 per year.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

 

Last Updated Saturday, April 22, 2017 - 11:35 PM.